LIAS (lipoic acid synthetase) is a mitochondrial enzyme that catalyzes the biosynthesis of lipoic acid, a critical cofactor for mitochondrial metabolism. The enzyme performs radical-mediated insertion of sulfur atoms to convert octanoylated protein domains into lipoylated derivatives on key mitochondrial enzymes involved in the TCA cycle 1. LIAS functions through direct interaction with ferredoxin 1 (FDX1), which serves as an essential electron donor and regulatory partner. This FDX1-LIAS interaction promotes functional binding to lipoyl carrier proteins like GCSH, enabling cellular protein lipoylation that is crucial for maintaining mitochondrial respiration and cell viability under metabolic stress conditions 1. Beyond its metabolic role, LIAS has emerged as a key regulator of cuproptosis, a copper-dependent form of cell death. In this pathway, LIAS works alongside FDX1 to mediate copper-induced cytotoxicity, with dysregulation of both proteins observed in various pathological conditions 23. Clinically, LIAS dysfunction is associated with severe metabolic disorders characterized by hyperglycinemia, lactic acidosis, and seizures. The protein's dual role in essential metabolism and regulated cell death makes it a potential therapeutic target in cancer, cardiovascular disease, and neurodegeneration 45.